Bird & Bird advised Lonza, while Goodwin and NautaDutilh advised Synaffix. SynAffix B.V. announced the sale to Lonza Group AG. Under the terms of the sale and...
Lonza’s Acquisition of Synaffix
Tay’s License Agreement with VYNE Therapeutics
Goodwin advised Tay on the agreement. Tay entered into a license agreement with VYNE Therapeutics, under which VYNE obtained exclusive rights to Tay’s oral BET inhibitor, TAY-B2...
Centauri Therapeutics’ $32 Million Series A Investment
Goodwin advised BIVF, Novo and Evotec on the deal. Boehringer Ingelheim Venture Fund GmbH (“BIVF”), Novo Holdings REPAIR Impact Fund (“Novo”) and Evotec SE (“Evotec”) led...
Artios Pharma Limited’s US$153 Million Series C Financing
Goodwin Procter advised Omega Funds on the deal. Artios Pharma Limited (Artios), a leading DNA Damage Response (DDR) company exploiting a broad DDR-based platform and small...